Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Conference News ACC 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

Michael O'Riordan

April 06, 2024

News Conference News THT 2023

More Early Insights Into Interatrial Shunts in HF, but Little to Focus the Field

Shelley Wood

March 24, 2023

News Industry News

Corvia Medical Announces Randomization of First Patient in the RESPONDER-HF Confirmatory Trial

December 06, 2022

News Features

A Hole in the Heart for HFpEF? Setbacks, Progress for Interatrial Shunts

Shelley Wood

July 07, 2022

News Daily News ESC Heart Failure 2022

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

Shelley Wood

May 22, 2022

News Industry News

Landmark REDUCE LAP-HF II Trial Demonstrates Clinical Benefit of Corvia Atrial Shunt in Large Segment of Heart Failure Patients

February 02, 2022

News Conference News THT 2022

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

Shelley Wood

February 01, 2022

News Industry News

Corvia Medical Completes Randomization In Reduce Lap-Hf II Pivotal Trial And Gains Fda Authorization To Provide Continued Access For The Corvia Atrial Shunt

November 17, 2020

News Conference News HFSA 2020

Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study

L.A. McKeown

October 12, 2020

News Industry News

Corvia Medical Announces Strong Positive One-Year Data From Reduce LAP-HF I Randomized, Sham-Controlled Clinical Trial

August 27, 2018

News Conference News AHA 2017

Novel Interatrial Shunt Succeeds in HF Hemodynamic Study: REDUCE LAP-HF I

Michael O'Riordan

November 21, 2017

News Industry News

Corvia Medical Announces Enrollment of First Patients in Pivotal Trial of the IASD System II for the Treatment of Heart Failure

November 14, 2017

Advertisement

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

More Early Insights Into Interatrial Shunts in HF, but Little to Focus the Field

Corvia Medical Announces Randomization of First Patient in the RESPONDER-HF Confirmatory Trial

A Hole in the Heart for HFpEF? Setbacks, Progress for Interatrial Shunts

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

Landmark REDUCE LAP-HF II Trial Demonstrates Clinical Benefit of Corvia Atrial Shunt in Large Segment of Heart Failure Patients

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

Corvia Medical Completes Randomization In Reduce Lap-Hf II Pivotal Trial And Gains Fda Authorization To Provide Continued Access For The Corvia Atrial Shunt

Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study

Corvia Medical Announces Strong Positive One-Year Data From Reduce LAP-HF I Randomized, Sham-Controlled Clinical Trial

Novel Interatrial Shunt Succeeds in HF Hemodynamic Study: REDUCE LAP-HF I

Corvia Medical Announces Enrollment of First Patients in Pivotal Trial of the IASD System II for the Treatment of Heart Failure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content